Problem of mild bronchial asthma revisited
It is estimated that 50-75% of bronchial asthma cases have mild (intermittent or persistent) severity of asthma. Despite the minimal number of daily symptoms, endobronchial inflammation and a high risk of exacerbations have been demonstrated in a significant proportion of patients. According to the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2019-08-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/3136 |
| _version_ | 1827961729298989056 |
|---|---|
| author | Y. G. Belotserkovskaya A. I. Sinopalnikov A. G. Romanovskikh I. P. Smirnov |
| author_facet | Y. G. Belotserkovskaya A. I. Sinopalnikov A. G. Romanovskikh I. P. Smirnov |
| author_sort | Y. G. Belotserkovskaya |
| collection | DOAJ |
| description | It is estimated that 50-75% of bronchial asthma cases have mild (intermittent or persistent) severity of asthma. Despite the minimal number of daily symptoms, endobronchial inflammation and a high risk of exacerbations have been demonstrated in a significant proportion of patients. According to the current guidelines, anti-inflammatory drugs - inhaled glucocorticosteroids - maintenance therapy is only added at stage 1, which is characterized by an insufficient level of control and repeated exacerbations due to the use of short-acting в-agonists to be taken as required. Inhaled glucocorticosteroids in low doses become the drugs of choice at stage 2 for patients with mild persistent bronchial asthma. As-needed use of inhaled glucocorticosteroids combined with в-agonists, which has a rapid onset of action (salbutamol or formoterol) may become an alternative to the daily used of drugs. The choice of such type of management should be justified by the low risk of exacerbation (based on an assessment of risk factors for adverse clinical out-comes/exacerbations of bronchial asthma). The as-needed use of such combination can provide a high patient commitment to medical recommendations, create a sufficient anti-inflammatory effect, reduce the likelihood of exacerbations and reduce the risk of adverse effects. |
| first_indexed | 2024-04-09T16:31:03Z |
| format | Article |
| id | doaj.art-b1d74007c7244e91b692beab12eeddf1 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:31:03Z |
| publishDate | 2019-08-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-b1d74007c7244e91b692beab12eeddf12023-04-23T06:57:05ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902019-08-01012707710.21518/2079-701X-2019-12-70-773043Problem of mild bronchial asthma revisitedY. G. Belotserkovskaya0A. I. Sinopalnikov1A. G. Romanovskikh2I. P. Smirnov3Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian FederationFederal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuous Professional Education» of the Ministry of Health of the Russian FederationIt is estimated that 50-75% of bronchial asthma cases have mild (intermittent or persistent) severity of asthma. Despite the minimal number of daily symptoms, endobronchial inflammation and a high risk of exacerbations have been demonstrated in a significant proportion of patients. According to the current guidelines, anti-inflammatory drugs - inhaled glucocorticosteroids - maintenance therapy is only added at stage 1, which is characterized by an insufficient level of control and repeated exacerbations due to the use of short-acting в-agonists to be taken as required. Inhaled glucocorticosteroids in low doses become the drugs of choice at stage 2 for patients with mild persistent bronchial asthma. As-needed use of inhaled glucocorticosteroids combined with в-agonists, which has a rapid onset of action (salbutamol or formoterol) may become an alternative to the daily used of drugs. The choice of such type of management should be justified by the low risk of exacerbation (based on an assessment of risk factors for adverse clinical out-comes/exacerbations of bronchial asthma). The as-needed use of such combination can provide a high patient commitment to medical recommendations, create a sufficient anti-inflammatory effect, reduce the likelihood of exacerbations and reduce the risk of adverse effects.https://www.med-sovet.pro/jour/article/view/3136mild asthmaas-need inhaled glucocorticosteroidsbeclomethasone/salbutamol |
| spellingShingle | Y. G. Belotserkovskaya A. I. Sinopalnikov A. G. Romanovskikh I. P. Smirnov Problem of mild bronchial asthma revisited Медицинский совет mild asthma as-need inhaled glucocorticosteroids beclomethasone/salbutamol |
| title | Problem of mild bronchial asthma revisited |
| title_full | Problem of mild bronchial asthma revisited |
| title_fullStr | Problem of mild bronchial asthma revisited |
| title_full_unstemmed | Problem of mild bronchial asthma revisited |
| title_short | Problem of mild bronchial asthma revisited |
| title_sort | problem of mild bronchial asthma revisited |
| topic | mild asthma as-need inhaled glucocorticosteroids beclomethasone/salbutamol |
| url | https://www.med-sovet.pro/jour/article/view/3136 |
| work_keys_str_mv | AT ygbelotserkovskaya problemofmildbronchialasthmarevisited AT aisinopalnikov problemofmildbronchialasthmarevisited AT agromanovskikh problemofmildbronchialasthmarevisited AT ipsmirnov problemofmildbronchialasthmarevisited |